GlobeNewswire

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
14/05/2026
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines [...]
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
14/05/2026
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of [...]
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV ® study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel [...]
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
14/05/2026
Achieved Q1 2026 PEMGARDA ® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Invivyd in vitro data showed continued neutralizing activity of [...]
ASHA and Hilarity for Charity Collaborate in Free, Online Event for Dementia Caregivers on May 20
14/05/2026
Rockville, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Communication difficulties are one of the hallmarks of dementia, and they can be among the more challenging everyday aspects for caregivers. To mark National Speech- [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
14/05/2026
WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will release its [...]
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
14/05/2026
BERKELEY HEIGHTS, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced a poster [...]
Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions
14/05/2026
Safe excretion of 7KC, a core driver of plaque associated with heart disease, stroke, inflammation, and age-related diseases, in humans suggests medicine could move beyond slowing heart disease to disease-modifying [...]
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
14/05/2026
– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously completed clinical [...]
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
14/05/2026
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model Results build upon prior preclinical evidence of [...]
XORTX Announces US$5 Million Public Offering
14/05/2026
CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2026 Guidance
14/05/2026
First Quarter Revenue was $647.9 million, a 15.9% increase over the prior year period First Quarter Net income was $41.7 million compared to $5.2 million for the prior year period Adjusted EBITDA for Q1 2026 was $84.4 [...]
American Shared Hospital Services Reports First Quarter 2026 Financial Results
14/05/2026
15.9% Revenue Growth Driven by Direct Patient Services Expansion; Operating Performance Improves Year-Over-Year Gross Margins Increased 36.7% Year-Over-Year Adjusted EBITDA Increased 18.4% Year-Over-Year Volumes [...]
BrewDog Shakes Up RTD Shelves Across the UK with New Nostalgia-Led Wonderland Cocktails
14/05/2026
Introducing Pear Drop Margarita & Fizzy Toffee Apple Martini ELLON, Scotland, May 14, 2026 (GLOBE NEWSWIRE) -- BrewDog , by Tilray Brands, Inc . (Nasdaq: TLRY; TSX: TLRY), is shaking up the ready-to-drink category [...]
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
14/05/2026
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a [...]
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed [...]
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
14/05/2026
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an [...]
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
14/05/2026
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 refractory [...]
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
14/05/2026
ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum